| 臺大學術典藏 |
2021-05-24T07:20:28Z |
Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan
|
CHEN-HUA LIU; Liu C.-J.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-06-25T08:10:15Z |
Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan
|
Liu C.-H.; Liu C.-J.; Su T.-H.; Yang H.-C.; CHUN-MING HONG; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-07-12T02:44:33Z |
Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan
|
Liu C.-H; | Liu C.-J; | Su T.-H; | HUNG-CHIH YANG; | Hong C.-M; | Tseng T.-C; | Chen P.-J; | Chen D.-S; | Kao J.-H. |
| 臺大學術典藏 |
2021-09-04T05:17:09Z |
Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan
|
Liu C.-H.; Liu C.-J.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2022-01-24T09:31:21Z |
Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan
|
Liu C.-H.; CHUN-JEN LIU; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:43:23Z |
Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan
|
Liu C.-H.; Liu C.-J.; TUNG-HUNG SU; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2019-02-27T06:48:01Z |
Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan
|
Tseng, Tai-Chung;JIA-HORNG KAO;DING-SHINN CHEN;PEI-JER CHEN;CHUN-MING HONG;HUNG-CHIH YANG;TUNG-HUNG SU;CHUN-JEN LIU;CHEN-HUA LIU; CHEN-HUA LIU; CHUN-JEN LIU; TUNG-HUNG SU; HUNG-CHIH YANG; CHUN-MING HONG; Tseng, Tai-Chung; PEI-JER CHEN; DING-SHINN CHEN; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-03-09T01:43:20Z |
Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan
|
Liu C.-H.; Liu C.-J.; TUNG-HUNG SU; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-05-24T07:20:25Z |
Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan
|
CHEN-HUA LIU; Liu C.-J.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-06-25T08:10:13Z |
Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan
|
Liu C.-H.; Liu C.-J.; Su T.-H.; Yang H.-C.; CHUN-MING HONG; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-07-12T02:44:29Z |
Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan
|
Liu C.-H; | Liu C.-J; | Su T.-H; | HUNG-CHIH YANG; | Hong C.-M; | Tseng T.-C; | Chen P.-J; | Chen D.-S; | Kao J.-H. |
| 臺大學術典藏 |
2021-09-04T05:16:58Z |
Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan
|
Liu C.-H.; Liu C.-J.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2022-01-24T09:31:17Z |
Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan
|
Liu C.-H.; CHUN-JEN LIU; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-07-03T03:33:35Z |
Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan
|
Liu C.-H.; Liu C.-J.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; PEI-JER CHEN; Chen D.-S.; Kao J.-H. |
| 國立成功大學 |
2019-05 |
Real-world effectiveness and safety of sofosbuvir plus daclatasvir with or without ribavirin for genotype 2 chronic hepatitis C in Taiwan
|
Cheng;Pin-Nan;Chiu;Yen-Cheng;Chien;Shih-Chieh;Chiu;Hung-Chih |
| 國立成功大學 |
2022-11 |
Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/ pibrentasvir for genotype 6 chronic hepatitis C
|
Chen;Jyh-Jou;Chiu;Yen-Cheng;Lee;Pei-Lun;Tung;Hung-Da;Chiu;Hung-Chih;Chien;Shih-Chieh;Cheng;Pin-Nan |
| 國立成功大學 |
2022 |
Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C
|
Chen, J.-J.;Chiu, Y.-C.;Lee, P.-L.;Tung, H.-D.;Chiu, H.-C.;Chien, S.-C.;Cheng, P.-N. |
| 臺大學術典藏 |
2021-03-09T01:43:14Z |
Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy
|
Yang H.-I.; Yeh M.-L.; Wong G.L.; Peng C.-Y.; Chen C.-H.; Trinh H.N.; Cheung K.-S.; Xie Q.; TUNG-HUNG SU; Kozuka R.; Lee D.-H.; Ogawa E.; Zhao C.; Ning H.-B.; Huang R.; Li J.; Zhang J.Q.; Ide T.; Xing H.; Iwane S.; Takahashi H.; Wong C.; Wong C.; Lin C.-H.; Hoang J.; Le A.; Henry L.; Toyoda H.; Ueno Y.; Gane E.J.; Eguchi Y.; Kurosaki M.; Wu C.; Liu C.; Shang J.; Furusyo N.; Enomoto M.; Kao J.-H.; Yuen M.-F.; Yu M.-L.; Nguyen M.H. |
| 臺大學術典藏 |
2021-09-04T05:16:43Z |
Real-world effectiveness from the asia pacific rim liver consortium for hbv risk score for the prediction of hepatocellular carcinoma in chronic hepatitis b patients treated with oral antiviral therapy
|
Yang H.-I.; Yeh M.-L.; Wong G.L.; Peng C.-Y.; Chen C.-H.; Trinh H.N.; Cheung K.-S.; Xie Q.; Su T.-H.; Kozuka R.; Lee D.-H.; Ogawa E.; Zhao C.; Ning H.-B.; Huang R.; Li J.; Zhang J.Q.; Ide T.; Xing H.; Iwane S.; Takahashi H.; Wong C.; Wong C.; Lin C.-H.; Hoang J.; Le A.; Henry L.; Toyoda H.; Ueno Y.; Gane E.J.; Eguchi Y.; Kurosaki M.; Wu C.; Liu C.; Shang J.; Furusyo N.; Enomoto M.; JIA-HORNG KAO; Yuen M.-F.; Yu M.-L.; Nguyen M.H. |
| 臺大學術典藏 |
2021-06-25T08:10:12Z |
Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data
|
CHUN-MING HONG; Liu C.-H.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen Y.-W.; Kao J.-H.; Liu C.-J. |
| 臺大學術典藏 |
2021-05-24T07:20:16Z |
Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data
|
Hong C.-M.; CHEN-HUA LIU; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen Y.-W.; Kao J.-H.; Liu C.-J. |
| 臺大學術典藏 |
2021-07-12T02:44:23Z |
Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data
|
Hong C.-M; | Liu C.-H; | Su T.-H; | HUNG-CHIH YANG; | Chen P.-J; | Chen Y.-W; | Kao J.-H; | Liu C.-J. |
| 臺大學術典藏 |
2022-01-24T09:31:06Z |
Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data
|
Hong C.-M.; Liu C.-H.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen Y.-W.; Kao J.-H.; CHUN-JEN LIU |
| 臺大學術典藏 |
2020 |
Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data
|
Liu C.-J.; Kao J.-H.; Chen Y.-W.; Chen P.-J.; Yang H.-C.; Su T.-H.; CHEN-HUA LIU; Hong C.-M. |
| 臺大學術典藏 |
2021-09-04T05:16:33Z |
Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data
|
Hong C.-M.; Liu C.-H.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen Y.-W.; JIA-HORNG KAO; Liu C.-J. |
